Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Trial Profile

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms DEVOTE
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 28 Oct 2019 Results evaluating the IHSG level 2 definition by applying it to a series of clinical trials in patients with type 1 or type 2 diabetes published in the Diabetes Care
    • 02 Jul 2019 Results of long-term cost-effectiveness of Insulin Degludec versus Insulin Glargine U100 by using data from DEVOTE trial published in the Applied Health Economics and Health Policy
    • 22 May 2019 Results of short-term cost-utility of degludec versus insulin glargine by using data from this study presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top